Literature DB >> 12473372

Small molecule antagonists of proteins.

Thomas R Gadek1, John B Nicholas.   

Abstract

The identification of small molecule antagonists of protein function is at the core of the pharmaceutical industry. Successful approaches to this problem, including screening and rational design, have been developed over the years to identify antagonists of enzymes and cellular receptors. These methods have been extended to the search for inhibitors of protein-protein interactions. While the very possibility of designing a small molecule inhibitor for such interactions was once doubted, there are examples of such inhibitors that are currently marketed products and many more inhibitors in various stages of research and development. Here we review the progress in identifying and designing small molecule protein inhibitors, with particular attention to those that block protein-protein interactions. We also discuss the physical character of protein-protein interfaces, and the resulting implications for small molecule lead discovery and design.

Mesh:

Substances:

Year:  2003        PMID: 12473372     DOI: 10.1016/s0006-2952(02)01479-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Are protein-protein interfaces more conserved in sequence than the rest of the protein surface?

Authors:  Daniel R Caffrey; Shyamal Somaroo; Jason D Hughes; Julian Mintseris; Enoch S Huang
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

2.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.

Authors:  Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-06       Impact factor: 11.205

3.  Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation.

Authors:  Yang Xu; Hong Lu; Jack P Kennedy; Xuxia Yan; Laura A McAllister; Noboru Yamamoto; Jason A Moss; Grant E Boldt; Shibo Jiang; Kim D Janda
Journal:  J Comb Chem       Date:  2006 Jul-Aug

4.  Inhibition of protein-protein interactions with low molecular weight compounds.

Authors:  Marilyn M Matthews; David J Weber; Paul S Shapiro; Andrew Coop; Alexander D Mackerell
Journal:  Curr Trends Med Chem       Date:  2008-01-01

5.  Synthesis and molecular docking studies of xanthone attached amino acids as potential antimicrobial and anti-inflammatory agents.

Authors:  Xing Chen; Jing Leng; K P Rakesh; N Darshini; T Shubhavathi; H K Vivek; N Mallesha; Hua-Li Qin
Journal:  Medchemcomm       Date:  2017-07-26       Impact factor: 3.597

6.  Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.

Authors:  Levi L Blazer; David L Roman; Alfred Chung; Martha J Larsen; Benjamin M Greedy; Stephen M Husbands; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2010-06-22       Impact factor: 4.436

7.  In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction.

Authors:  Paul T Wilder; Thomas H Charpentier; Melissa A Liriano; Kira Gianni; Kristen M Varney; Edwin Pozharski; Andrew Coop; Eric A Toth; Alex D Mackerell; David J Weber
Journal:  Int J High Throughput Screen       Date:  2010-07-07

8.  Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.

Authors:  Lawrence K Lee; Katherine J Bryant; Romaric Bouveret; Pei-Wen Lei; Anthony P Duff; Stephen J Harrop; Edwin P Huang; Richard P Harvey; Michael H Gelb; Peter P Gray; Paul M Curmi; Anne M Cunningham; W Bret Church; Kieran F Scott
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

Review 9.  Regulation of enzyme activity through interactions with nanoparticles.

Authors:  Zhaochun Wu; Bin Zhang; Bing Yan
Journal:  Int J Mol Sci       Date:  2009-11-20       Impact factor: 6.208

10.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.